[Helicobacter pylori: changes of indications for eradication therapy].
Koop
H
H
II. Innere Klinik -- Gastroenterologie, HELIOS Klinikum Berlin-Buch, Berlin. hkoop@berlin.helios-kliniken.de
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008134:Long-Term Care; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001241:Aspirin
Helicobacter pylori: Wandel im Eradikationsspektrum.